DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
McInnes IB, Sieper J, Braun J. et al.
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A
monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a
24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept
trial.
Ann Rheum Dis 2014;
73: 349-356
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.